Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 668.8 Million USD | -23.6% |
| 2023 | 875.43 Million USD | 21.21% |
| 2022 | 722.22 Million USD | -8.97% |
| 2021 | 793.36 Million USD | 16.45% |
| 2020 | 681.31 Million USD | 9.59% |
| 2019 | 621.71 Million USD | 0.13% |
| 2018 | 620.91 Million GBP | 4.12% |
| 2017 | 596.34 Million GBP | 14.89% |
| 2016 | 519.07 Million GBP | 30.26% |
| 2015 | 398.5 Million GBP | 7.07% |
| 2014 | 372.2 Million GBP | 7.79% |
| 2013 | 345.3 Million GBP | 1.02% |
| 2012 | 341.8 Million GBP | 10.29% |
| 2011 | 309.9 Million GBP | 8.62% |
| 2010 | 285.3 Million GBP | 1.75% |
| 2009 | 280.4 Million GBP | 13.48% |
| 2008 | 247.1 Million GBP | 5.69% |
| 2007 | 233.8 Million GBP | 16.2% |
| 2006 | 201.2 Million GBP | 9.8% |
| 2005 | 183.24 Million GBP | -0.25% |
| 2004 | 183.71 Million GBP | 6.32% |
| 2003 | 172.79 Million GBP | 7.71% |
| 2002 | 160.42 Million GBP | -1.51% |
| 2001 | 162.87 Million GBP | 21.79% |
| 2000 | 133.73 Million GBP | 133.78% |
| 1999 | 57.2 Million GBP | 20.32% |
| 1998 | 47.54 Million GBP | 1.96% |
| 1997 | 46.63 Million GBP | -2.64% |
| 1996 | 47.89 Million GBP | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 166.8 Million GBP | -61.29% |
| 2024 Q2 | 424.67 Million USD | 154.6% |
| 2024 FY | 845.56 Million USD | -3.41% |
| 2024 Q4 | 423.79 Million USD | 0.0% |
| 2023 Q2 | 423.53 Million USD | 141.88% |
| 2023 Q1 | 175.1 Million GBP | 12.17% |
| 2023 Q3 | 169.75 Million GBP | -59.92% |
| 2023 Q4 | 430.92 Million USD | 153.86% |
| 2023 FY | 875.43 Million USD | 21.21% |
| 2022 Q1 | 140.6 Million GBP | -2.56% |
| 2022 FY | 722.22 Million USD | -8.97% |
| 2022 Q3 | 156.1 Million GBP | 11.02% |
| 2022 Q2 | 140.6 Million USD | 0.0% |
| 2022 Q4 | 156.1 Million USD | 0.0% |
| 2021 FY | 793.36 Million USD | 16.45% |
| 2021 Q2 | 142.85 Million USD | 0.0% |
| 2021 Q1 | 142.85 Million GBP | 1.78% |
| 2021 Q4 | 144.3 Million USD | 0.0% |
| 2021 Q3 | 144.3 Million GBP | 1.02% |
| 2020 Q2 | 135.35 Million USD | 0.0% |
| 2020 Q4 | 140.35 Million USD | 0.0% |
| 2020 FY | 681.31 Million USD | 9.59% |
| 2020 Q1 | 135.35 Million GBP | 8.41% |
| 2020 Q3 | 140.35 Million GBP | 3.69% |
| 2019 Q1 | 119.4 Million GBP | 3.06% |
| 2019 Q3 | 124.85 Million GBP | 4.56% |
| 2019 FY | 621.71 Million USD | 0.13% |
| 2019 Q4 | 124.85 Million USD | 0.0% |
| 2019 Q2 | 119.4 Million GBP | 0.0% |
| 2018 Q1 | 119.3 Million GBP | 0.68% |
| 2018 Q2 | 119.3 Million GBP | 0.0% |
| 2018 FY | 620.91 Million GBP | 4.12% |
| 2018 Q3 | 115.85 Million GBP | -2.89% |
| 2018 Q4 | 115.85 Million GBP | 0.0% |
| 2017 Q4 | 118.5 Million GBP | 0.0% |
| 2017 FY | 596.34 Million GBP | 14.89% |
| 2017 Q1 | 111.05 Million GBP | 11.05% |
| 2017 Q2 | 111.05 Million GBP | 0.0% |
| 2017 Q3 | 118.5 Million GBP | 6.71% |
| 2016 FY | 519.07 Million GBP | 30.26% |
| 2016 Q4 | 100 Million GBP | 0.0% |
| 2016 Q3 | 100 Million GBP | 6.21% |
| 2016 Q2 | 94.15 Million GBP | 0.0% |
| 2016 Q1 | 94.15 Million GBP | -5.85% |
| 2015 FY | 398.5 Million GBP | 7.07% |
| 2015 Q3 | 100 Million GBP | 0.76% |
| 2015 Q1 | 99.25 Million GBP | 4.2% |
| 2015 Q2 | 99.25 Million GBP | 0.0% |
| 2015 Q4 | 100 Million GBP | 0.0% |
| 2014 Q4 | 95.25 Million GBP | 0.0% |
| 2014 FY | 372.2 Million GBP | 7.79% |
| 2014 Q3 | 95.25 Million GBP | 4.84% |
| 2014 Q2 | 90.85 Million GBP | 0.0% |
| 2014 Q1 | 90.85 Million GBP | 2.02% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | 345.3 Million GBP | 1.02% |
| 2013 Q4 | 89.05 Million GBP | 0.0% |
| 2013 Q3 | 89.05 Million GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | 341.8 Million GBP | 10.29% |
| 2011 FY | 309.9 Million GBP | 8.62% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | 285.3 Million GBP | 1.75% |
| 2010 Q2 | - GBP | 0.0% |
| 2009 FY | 280.4 Million GBP | 13.48% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 247.1 Million GBP | 5.69% |
| 2007 Q2 | - GBP | 0.0% |
| 2007 FY | 233.8 Million GBP | 16.2% |
| 2006 FY | 201.2 Million GBP | 9.8% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | 183.24 Million GBP | -0.25% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2004 FY | 183.71 Million GBP | 6.32% |
| 2003 FY | 172.79 Million GBP | 7.71% |
| 2002 FY | 160.42 Million GBP | -1.51% |
| 2001 FY | 162.87 Million GBP | 21.79% |
| 2000 FY | 133.73 Million GBP | 133.78% |
| 1999 FY | 57.2 Million GBP | 20.32% |
| 1998 FY | 47.54 Million GBP | 1.96% |
| 1997 FY | 46.63 Million GBP | -2.64% |
| 1996 FY | 47.89 Million GBP | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -883107.438% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -3571.095% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -443.944% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -34516.977% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -4140.157% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -3795371.313% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -3013.884% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1017426.777% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -11231.752% |
| Marizyme, Inc. | 645.81 Thousand USD | -103459.871% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -172.628% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -675496.501% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -162956.331% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -871175.778% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -1692293.34% |
| MultiCell Technologies, Inc. | 49.32 USD | -1356042073.56% |
| ONE Bio Corp. | 52.29 Million USD | -1178.869% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -1245.106% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1367589.162% |
| Q BioMed Inc. | 284.35 Thousand USD | -235101.44% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -2159.688% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -360.925% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -119818.954% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -955328.571% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -101464.161% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 95.447% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -66946846.947% |
| Enzolytics Inc. | 52.79 Thousand USD | -1266662.634% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -109805.098% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 45.463% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -476789.947% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -108228.042% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 20.336% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -66932.432% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -1283.133% |
| BioStem Technologies, Inc. | 16.68 Million USD | -3908.293% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -282618.972% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -282618.972% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -48753.178% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -141077.464% |
| SYBLEU INC | 11.69 Thousand USD | -5718094.254% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -8486.468% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -5144515.385% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -1691608.403% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -19984.084% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -9934.509% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -64269.586% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -2495.568% |
| CSL Limited | 14.8 Billion USD | 95.481% |
| Cellectis S.A. | 755 Thousand USD | -88482.781% |